FDA Approves Antibiotic for Skin Infections
Dalvance was given priority review and designated a "Qualified Infectious Disease Product" since it's meant to treat serious bacterial or fungal infections, the FDA said in a news release.
The drug's safety and effectiveness were evaluated in clinical studies involving nearly 1,300 people with acute bacterial skin infections. The most common side effects were nausea, headache and diarrhea. Study participants who took Dalvance also showed a higher-than-expected incidence of elevated liver enzymes in one screening test, the agency said.
Dalvance is marketed by Durata Therapeutics of Chicago.
More information
The FDA has more about this approval.
Sarra Sounds Off, Ep. 17: Olympics a possibility for Long Beach wrestler? On the latest episode of "Sarra Sounds Off," Newsday's Gregg Sarra talks with Long Beach wrestler Dunia Sibomana-Rodriguez about pursuing a third state title and possibly competing in the Olympics in 2028, plus Jared Valluzzi has the plays of the week.
Sarra Sounds Off, Ep. 17: Olympics a possibility for Long Beach wrestler? On the latest episode of "Sarra Sounds Off," Newsday's Gregg Sarra talks with Long Beach wrestler Dunia Sibomana-Rodriguez about pursuing a third state title and possibly competing in the Olympics in 2028, plus Jared Valluzzi has the plays of the week.
